★ Market InsightsBiotechnology & Healthcare Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…McAlinden Research PartnersJanuary 4, 2022
★ Market InsightsBiotechnology & HealthcareMarkets Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022 Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…McAlinden Research PartnersDecember 22, 2021
